WHY CHOOSE REUTERINA®?
To be widely used, a probiotic must be safe. Lactobacillus reuteri strain DSM17938 (the bacteria contained in Reuterina®) was originally isolated from human milk and is a natural coloniser of both the stomach and the small intestine2,4.
Lactobacilli are generally regarded as non-pathogenic (do not cause infection), because they occur naturally in the intestine4.
Reuterina® has a role to play in the prevention and treatment of a variety of disorders, associated with an imbalance of flora, such as5-20;
- Functional gastrointestinal disorders (colic, regurgitation, constipation and abdominal pain)
- Acute gastroenteritis (infection)
- Antibiotic associated diarrhoea
- Infection protection via immune modulation in the gut
Reuterina® has been clinically validated in over 200 clinical trials21.
Reuterina® contains live freeze-dried bacteria, the content and viability of which is guaranteed until expiry. These bacterial strains are isolated from human origin with well-documented safety and stability in humans22-26.
WHAT ARE PROBIOTICS?
Probiotics are viable (“live”) non-pathogenic bacteria that colonise the intestine and modify the intestinal microflora. By modulating the gut microbiota, probiotics have the ability to exert health-promoting activities beneficial for the host1,3.
THE PROBIOTIC FOR LIFE
Reuterina® plays a multifaceted role in family health.
A balanced gut flora has multiple effects on the entire body. Reuterina® promotes good flora balance throughout the entire body21-27.
Reuterina® is clinically proven for the reduction of gut disorders throughout life5,8-9,11,14,17.
Colic
Constipation
Diarrhoea
Functional
Abdominal Pain
Immune Modulation
Women’s Health
OUR PRODUCTS
Reuterina® provides a full range of products for all ages.
WHAT THE PROFESSIONALS SAY
The Reuterina® strains are clinically proven in over 140 human trials and sold in over 90 countries worldwide, making us a truly global probiotic.
I was introduced to Reuterina™ when I became a first mom 5 years ago. Ever since then, I’ve made sure that there is always one available in my medicine cabinet. I absolutely love it and I think it is a must have product especially when you are traveling. Everyone at home uses it because Reuterina™ has something for everyone in the family.
– Shan o-founder of You, Baby and I (https://www.youbabyandi.com/reuterina-drops)
OUR STOCKISTS
The Reuterina® range is available at Clicks, Dis-Chem and all major Pharmacies across South Africa. Locate it in a store near you.
CONTACT US
Please note: This email address is not monitored 24/7. Please expect feedback within 48 hours.
Should you require medical advise or have a question of a medical nature, please contact your HealthCare practitioner directly.
FOOTNOTES
One dose of Reuterina™ Protectis® – 5 drops (0,2 ml)/1 chew tablet – contains a minimum of 100 million (1 x 108) live, freeze-dried colony forming units (CFU) Lactobacillus reuteri Protectis® (strain DSM 17938) until expiry.22c,23c,24c,25c,26c
One dose of Reuterina™ Femme – 1 capsule – contains 2,5 billion (2,5 x 109) colony forming units (CFU) Lactobacillus rhamnosus GR-1 and 2,5 billion (2,5 x 109) colony forming units CFU Lactobacillus reuteri RC-14 until expiry. Total probiotic bacteria: 5 billion (5 x 109).27c
One Reuterina™ Lozenge contains a minimum of 100 million (1 x 10⁸) live, freeze-dried colony forming units (CFU) Lactobacillus reuteri (strain DSM 17938) and a minimum of 100 million (1 x 10⁸) live, freeze-dried colony forming units (CFU) of Lactobacillus reuteri (ATCC PTA 5289) until expiry. Total probiotic bacteria: 200 million (2 x 10⁸) CFU.28c
- Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria, October 2001. http://www.fao.org/3/a-a0512e.pdf Last accessed September 2019.
- Eom T-H, et al. The therapeutic effect of Lactobacillus reuteri in acute diarrhea in infants and toddlers. Korean J Ped 2005;48:986-989.
- Gottteland M, et al. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Aliment Pharmacol Ther 2006;23:1077–1086.
- Weizman Z, et al. Effect of a probiotic infant formula on infections in child-care centers: Comparison of two probiotic agents. Pediatrics 2005;115:5-9.
- Savino F, Pelle E, Palumeri E, et al. Lactobacillus reuteri (American Type Culture Collection Strain 55730) Versus Simethicone in the Treatment of Infantile Colic: A Prospective Randomized Study. Pediatrics 2007;119:e124.
- Mi GL, Zhao L, Qiao DD, et al. Effectiveness of Lactobacillus reuteri in infantile colic and colicky induced maternal depression: a prospective single blind randomized trial. Antonie Van Leeuwenhoek 2015;107(154):1557-1553.
- Chau K, et al. Probiotics for infantile colic: a randomized double-blind placebo-controlled trial investigating Lactobacillus reuteri DSM 17938. J Pediatr 2014;166:74-78.
- Szajewska H, et al. Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: A randomized, double-blind, placebo-controlled trial. J Pediatr 2013;162:257-262.
- Indrio F, et al. The effects of probiotics on feeding tolerance, bowel habits, and gastrointestinal motility in preterm newborns. J Pediatr 2008;152:801-806.
- Indrio F, et al. Lactobacillus reuteri accelerates gastric emptying and improves regurgitation in infants. Eur J Clin Invest 2011;41:417-422.
- Indrio F, et al. Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional constipation. A randomized clinical trial. JAMA Pediatr 2014;168:228-233.
- Olgac MAB, et al. Comparison of probiotic and lactulose treatments in children with functional constipation and determination of the effects of constipation treatment on quality of life. Cocuk Sağlığı ve Hastalıkları Dergisi [Turkish Pediatric Journal] 2013;56: 1-7.
- Coccorullo P, et al. Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation:a double-blind, randomized, placebo-controlled study. J Pediatrics 2010;157:598-602.
- Weizman Z, et al. Lactobacillus reuteri DSM 17938 for the management of functional abdominal pain in childhood: a randomized, double-blind, placebo-controlled trial. J Pediatr 2016;174:160-164.
- Romano C, et al. Lactobacillus reuteri in children with functional abdominal pain (FAP). J Paediatr Child Health 2014;50(10):E68-E71.
- Jadresin O, et al. Lactobacillus reuteri DSM 17938 in the treatment of functional abdominal pain in children – RCT study. J Pediatr Gastroenterol Nutr 2017;64:925-929.
- Ojetti V, laniro G, Tortora A, et al. Effect of Lactobacillus reuteri. supplementation in adults with chronic functional constipation: a randomised double-blind. placebo-controlled trial. J Gastrointestin Liver Dis 2014;23:387-391.
- Cimperman L, Bayless G, Best K, et al. A randomized. Double-blind. Placebo-controlled pilot study of Lactobacillus reuteri ATCC 55730 for the prevention of antibiotic-associated diarrhoea in hospitalized adults. J Clin Gastroenterol 2011;45:785-789.
- Gutierrez-Castrellon P, et al. Diarrhea in preschool children and Lactobacillus reuteri: a randomized controlled trial. Pediatrics 2014;133:4 e904-e909.
- Agustina R, et al. Randomized trial of probiotics and calcium on diarrhea and respiratory tract infections in Indonesian children. Pediatrics 2012;129:e1155-e1164.
- Data on file.
- Reuterina™ Drops Approved Package Insert, August 2009.
- Reuterina™ Vit D (drops) Approved Package Insert, August 2013.
- Reuterina™ Junior Approved Package Insert, July 2010.
- Reuterina™ Daily Approved Package Insert, July 2010.
- Reuterina™ Acute Approved Package Insert, March 2010.
- Reuterina™ Femme Approved Package Insert, December 2009.
- Reuterina™ Lozenges Approved Package Insert, October 2017.
One dose of Reuterina™ Protectis® – 5 drops (0,2 ml)/1 chew tablet – contains a minimum of 100 million (1 x 108) live, freeze-dried colony forming units (CFU) Lactobacillus reuteri Protectis® (strain DSM 17938) until expiry.22c,23c,24c,25c,26c
One dose of Reuterina™ Femme – 1 capsule – contains 2,5 billion (2,5 x 109) colony forming units (CFU) Lactobacillus rhamnosus GR-1 and 2,5 billion (2,5 x 109) colony forming units CFU Lactobacillus reuteri RC-14 until expiry. Total probiotic bacteria: 5 billion (5 x 109).27c
One Reuterina™ Lozenge contains a minimum of 100 million (1 x 10⁸) live, freeze-dried colony forming units (CFU) Lactobacillus reuteri (strain DSM 17938) and a minimum of 100 million (1 x 10⁸) live, freeze-dried colony forming units (CFU) of Lactobacillus reuteri (ATCC PTA 5289) until expiry. Total probiotic bacteria: 200 million (2 x 10⁸) CFU.28c
This page is not intended to give medical advise or replace any medical advise received from a Healthcare practitioner. It is always recommended that a healthcare practitioner is contacted before consuming any product.
